NASDAQ$NBIX
Neurocrine Biosciences Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Neurocrine Biosciences reported financial results for Q3 2021, highlighted by INGREZZA's net product sales of $287 million and record total prescriptions.
Neurocrine Biosciences announced positive financial results for the third quarter of 2021, with INGREZZA's continued growth driving revenue. The company is expanding its commercial footprint and investing in its R&D pipeline, with several clinical data read-outs expected over the next two years.
- Third quarter net product sales for INGREZZA were $287 million.
- Record total prescriptions were achieved during the third quarter 2021, reflecting higher customer demand.
- New prescriptions increased throughout the third quarter, reaching their highest levels since March 2020.
- The company is expanding its commercial organization in 2022 to better meet the needs of healthcare professionals.
Headline financials
Revenue & EPS history
Neurocrine Biosciences · Revenue · Quarterly
$296M
Revenue by segment
Neurocrine Biosciences · $294M total across 2 segments · Q3 2021
- INGREZZA Net Product Sales$287M+13.0%97.6%
- CRENESSITY Net Product Sales$7.2M—2.4%
Forward guidance
Neurocrine Biosciences provides full-year 2021 expense guidance, with combined GAAP R&D and SG&A expenses expected to be between $895 million and $915 million, and combined Non-GAAP R&D and SG&A expenses expected to be between $760 million and $780 million.
Tailwinds
- Registrational top-line data for Valbenazine in Chorea in Huntington Disease expected in December.
- Mitsubishi Tanabe Pharma Corporation submitted Marketing Authorization with Ministry of Health and Welfare in Japan for Tardive Dyskinesia.
- Initiating Registrational Study in Q4 for Dyskinesia Due to Cerebral Palsy.
- Initiating Registrational Study in November for Adjunctive Treatment in Schizophrenia.
- Enrolling Registrational Study for Crinecerfont in Congenital Adrenal Hyperplasia (Adult).
Headwinds
- Risks associated with the commercialization of INGREZZA and ONGENTYS.
- The impact of the evolving COVID-19 pandemic on our business and the business operations of our customers.
- Risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions.
- Risk and uncertainties related to any COVID-19 quarantine, social distancing and other requirements put in place by governments, customers, or clinical trial sites, including the impact of such requirements on the ability of patients to have in-person visits with their health care provider.
- Risks related to the development of our product candidates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+1.6%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+17.2%
Q3 2017
Best reaction
-18.5%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | +11.5% | +21.3% | |
| Q4 2025 | -10.4% | -7.0% | -5.6% | |
| Q3 2025 | -6.3% | -3.7% | +3.2% | |
| Q1 2025 | +8.3% | +5.4% | +13.5% | |
| Q4 2024 | -18.5% | -22.1% | -24.9% | |
| Q3 2024 | +3.5% | +3.7% | +9.1% | |
| Q2 2024 | +8.2% | +2.9% | -10.2% | |
| Q1 2024 | +1.7% | +3.0% | -1.5% | |
| Q4 2023 | -6.0% | -8.8% | -2.6% | |
| Q3 2023 | +4.1% | +5.0% | +8.8% | |
| Q2 2023 | +2.2% | -0.3% | +6.9% | |
| Q1 2023 | -7.4% | -5.4% | -10.8% | |
| Q4 2022 | -5.6% | -6.2% | -11.1% | |
| Q3 2022 | +6.0% | +5.8% | +9.7% | |
| Q2 2022 | +10.6% | +14.5% | +9.5% | |
| Q1 2022 | -3.9% | -14.6% | +7.7% | |
| Q4 2021 | +8.7% | +7.9% | +12.2% | |
| Q3 2021 | -9.3% | -11.6% | -23.4% | |
| Q2 2021 | -2.8% | -6.6% | +0.4% | |
| Q1 2021 | -2.3% | -0.3% | +3.2% | |
| Q4 2020 | +3.1% | +2.6% | -17.3% | |
| Q3 2020 | -9.1% | -4.5% | -4.5% | |
| Q2 2020 | -0.2% | -4.4% | -3.7% | |
| Q1 2020 | +7.0% | +11.6% | +13.8% | |
| Q4 2019 | +2.0% | +3.5% | -5.4% | |
| Q3 2019 | -1.2% | +6.9% | +14.4% | |
| Q2 2019 | +9.7% | +7.5% | +11.3% | |
| Q1 2019 | -6.7% | +2.0% | +1.4% | |
| Q4 2018 | -4.6% | -4.6% | -12.9% | |
| Q3 2018 | -8.0% | -9.0% | -25.5% | |
| Q2 2018 | +14.7% | +17.2% | +23.3% | |
| Q1 2018 | +3.3% | +1.5% | +17.1% | |
| Q4 2017 | +3.9% | +3.7% | +11.6% | |
| Q3 2017 | +17.2% | +20.0% | +18.5% | |
| Q2 2017 | +10.2% | +10.5% | +17.4% | |
| Q1 2017 | +3.4% | +3.8% | -15.3% | |
| Q4 2016 | +0.7% | +4.5% | +7.2% | |
| Q3 2016 | -10.0% | -1.1% | -3.1% | |
| Q2 2016 | -0.7% | -3.6% | -2.0% | |
| Q1 2016 | -0.1% | — | — | |
| Q4 2015 | +6.9% | — | — | |
| Q3 2015 | -4.5% | — | — | |
| Q2 2015 | -3.7% | — | — | |
| Q1 2015 | -4.4% | — | — | |
| Q4 2014 | +5.7% | — | — | |
| Q3 2014 | -4.9% | — | — | |
| Q2 2014 | -2.3% | — | — | |
| Q1 2014 | -3.5% | — | — | |
| Q4 2013 | +1.3% | — | — | |
| Q3 2013 | -6.3% | — | — | |
| Q2 2013 | +0.5% | — | — | |
| Q1 2013 | +2.3% | — | — | |
| Q4 2012 | +6.5% | — | — | |
| Q3 2012 | -1.7% | — | — | |
| Q2 2012 | -9.6% | — | — | |
| Q1 2011 | -3.2% | — | — | |
| Q1 2012 | -3.2% | — | — | |
| Q4 2011 | -8.0% | — | — | |
| Q4 2009 | -8.0% | — | — | |
| Q3 2010 | +13.7% | — | — | |
| Q3 2011 | +13.7% | — | — | |
| Q4 2010 | -6.5% | — | — | |
| Q2 2010 | -6.5% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q1 2010 | -1.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro